Activation of the glucagon-like peptide 1 (GLP-1 ... Semaglutide is a GLP-1 receptor agonist that has been approved by the US Food and Drug Administration and is currently marketed in various dosage ...

Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a ...

Cardiologists need to embrace the wave of new drugs, say experts, particularly since they can reduce the risk of CVD.

In June 2025, Carmot Therapeutics Inc. announced a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of ...

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal Therapy SHANGHAI, June 2 ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

Mumbai: Novo Nordisk, a global healthcare company headquartered in Denmark, has announced the launch of Wegovy (injectable ...

The loss of Novo’s involvement significantly dented investor confidence in Hims & Hers, plunging shares in the latter by 35% ...

The latter function is performed by the islets of Langerhans, cells in the pancreas (named after their discoverer, ...